Background: During the development of recommendations and implementation aids of the GECOAx project, the importance of avoiding certain situations was highlighted.
Objectives:
To recognize what prescriptions, risk assessments, or preventive strategies are wrong practices and should thus be avoided in clinical practice. To establish not to do recommendations in the management of the comorbidity of AxSpA. Methods: A multidisciplinary group was selected [10 rheumatologists, 1 internist, 1 cardiologist, 1 gastroenterologist, 1 psychologist and 2 family physicians]. With the support of 3 methodologists, and after interactions aimed to edit a document for the management of comorbidity launched by the same panel, a list of Not to do recommendations was issued. In a discussion meeting, evidence was provided to support the recommendations, items without sufficient basis were removed, and the final list was produced. Results: A summary list of Not to do recommendations (Table 1) was issued. Table 1 -DO NOT prescribe NSAIDs to patients with high cardiovascular (CV) risk and particularly with hypertension.
-DO NOT prescribe NSAIDs to patients with CKD, heart failure or liver cirrhosis and, if necessary, exert caution. -DO NOT use CV risk scores in patients who already suffered a CV event or those with multiple risk factors (smoking, obesity, sedentary lifestyle, DM, hypertension, dyslipidemia) or a family history of premature CV disease; All should be considered high CV risk.
-DO NOT base renal disease screening on a single glomerular filtration test and/or albuminuria (ALWAYS should be confirmed); serum creatinine should not be used as the only test to evaluate renal function. -DO NOT administer biological therapy in case of active, serious and uncontrolled infection, sepsis or risk of sepsis or tuberculosis or without a previous screening of chronic HBV, HCV, HIV and TB. We observed no statistical differences in axial or peripheral affection according to the IBD diagnosis. 79 cases were on biological therapy, and these treatments were conducted by Rheumatology in the 44% of cases and by Digestive Department in the 66% of cases. We observed that patients with axial affection present higher probability that the treatment has been conducted by Rheumatology (P=0.007), and broken down axial affections AS diagnosis had the most probability to be conducted by Rheumatology (n=36 P=0.0102). Related to peripheral manifestations, uveitis diagnosis had the most probability to be conducted by Rheumatology (n=14 P=0.0337).
Conclusions:
In our patient series with IBD and musculoskeletal manifestations, the most common were peripheral affection. Among patients with IBD and axial and/or peripheral manifestation, 44% were conducted by Rheumatology, and are cases with axial predominance, where IBD treatment does not improve musculoskeletal disease and a primary spondyloarthritis treatment is needed. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5687
